stoxline Quote Chart Rank Option Currency Glossary
  
AEON Biopharma, Inc. (AEON)
0.129  -0.001 (-0.77%)    02-14 16:00
Open: 0.1235
High: 0.129
Volume: 3,062,019
  
Pre. Close: 0.13
Low: 0.1211
Market Cap: 10(M)
Technical analysis
2025-02-14 4:46:07 PM
Short term     
Mid term     
Targets 6-month :  0.2 1-year :  0.26
Resists First :  0.17 Second :  0.22
Pivot price 0.12
Supports First :  0.1 Second :  0.08
MAs MA(5) :  0.13 MA(20) :  0.12
MA(100) :  0.61 MA(250) :  2.79
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  48.3 D(3) :  47.7
RSI RSI(14): 33.3
52-week High :  17.17 Low :  0.1
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AEON ] has closed below upper band by 46.6%. Bollinger Bands are 94.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.13 - 0.13 0.13 - 0.13
Low: 0.12 - 0.12 0.12 - 0.12
Close: 0.13 - 0.13 0.13 - 0.13
Company Description

AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.

Headline News

Mon, 10 Feb 2025
AEON Biopharma Receives Notice Of Non-Compliance With NYSE American Listing Standards - Nasdaq

Fri, 07 Feb 2025
Aeon Biopharma Gets NYSE American Noncompliance Notice -February 07, 2025 at 05:06 pm EST - Marketscreener.com

Fri, 07 Feb 2025
AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards - TradingView

Mon, 20 Jan 2025
Irvine-based Aeon Biopharma Raises $20 Million - Orange County Business Journal

Fri, 10 Jan 2025
AEON’s Value Tanks As It Closes $20m Offering Amid Botox Biosimilar Aspirations - News & Insights

Tue, 07 Jan 2025
AEON Biopharma Raises $20M in Public Offering with Dual-Warrant Structure - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 40 (M)
Shares Float 18 (M)
Held by Insiders 36.6 (%)
Held by Institutions 23.8 (%)
Shares Short 127 (K)
Shares Short P.Month 623 (K)
Stock Financials
EPS -0.16
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.71
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -597.7 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.11
Qtrly Earnings Growth 0 %
Operating Cash Flow -43 (M)
Levered Free Cash Flow -25 (M)
Stock Valuations
PE Ratio -0.86
PEG Ratio 0
Price to Book value -0.19
Price to Sales 0
Price to Cash Flow -0.12
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android